GMP IPO
📋 Filings Intelligence
About Contact
LIVE - Auto-updated every 10 mins · Equity segment
Company Filings, Explained Simply

AI-powered plain-English analysis of every important corporate announcement - financial results, order wins, dividends, mergers and more. Updated live.

-
Filed today
-
Companies tracked
NSE & BSE
Listed on
Sign in free to search by company
Filing Type
Market Cap
Sector
All Sectors

Latest Filings -

📋 Filing Types Available on ForgeUp Filings Sourced from BSE corporate announcements (equity segment). Companies covered are BSE-listed and most are also listed on NSE. We show only material filings.
Financial Results Orders Dividend Buyback Merger / Acquisition Board Meeting Outcome Fundraise (QIP / Rights / FPO) Regulatory / Court Order Credit Rating Change Promoter Pledge Update Management Change Joint Venture / MOU Delisting Bonus Shares Stock Split
Data sourced from BSE India corporate announcements. More categories will be added over time.
Gland Pharma Ltd

Gland Pharma Q2 FY27 Consolidated Net Profit Rises 58.26% to ₹2,907.56 million

RESULTS ▲ Positive Development LOW RISK
📅 Filed on BSE: 06 Nov 2026, 04:59 PM IST  ·  BSE ID: b78b1f7c-8972-4b73-b3cf-517c533a742c
View Original BSE Filing (PDF)
💡
In Simple Terms
Gland Pharma reported its financial results, showing an increase in revenue and profit for the quarter and half year ending September 2026.
🤖 AI Summary
  • Gland Pharma's consolidated revenue from operations was ₹18,335.88 million for Q2 FY27.
  • Consolidated net profit for Q2 FY27 stood at ₹2,907.56 million, up from ₹1,836.84 million YoY.
  • Half-year consolidated revenue reached ₹36,338.59 million for the period ended September 30, 2026.
  • Half-year consolidated net profit was ₹6,077.15 million, compared to ₹3,991.66 million last year.
  • The Board of Directors approved the unaudited financial results for the quarter and half year.
🔢 Key Numbers - exact figures from BSE filing, not rounded
Revenue from operations (Q2 FY27)
18,335.88 million
23.32%
Net Profit for the period (Q2 FY27)
2,907.56 million
58.26%
Revenue from operations (Half-year FY27)
36,338.59 million
21.43%
Net Profit for the period (Half-year FY27)
6,077.15 million
52.24%
Total Comprehensive Income (Q2 FY27)
3,145.22 million
9.71%
🏢 How This Affects the Company
📈
Business Impact
The increased revenue from operations indicates sustained business activity and market demand for Gland Pharma's products in Q2 FY27.
💰
Financial Impact
Improved net profit margins reflect efficient cost management and increased sales contributing positively to earnings for the quarter and half year.
👥 What This Means For Shareholders
✅
Action Required
No immediate action is required by shareholders based on this financial results filing.
👤
Who Is Affected
All shareholders are affected by the company's financial performance, which showed consolidated net profit of ₹2,907.56 million for the quarter.
🔍
Management Signal
The approval of robust financial results signals management's focus on operational efficiency and profitability, alongside continued business growth.

For information only. Not investment advice. ForgeUp is not SEBI-registered.

👁 Watch List - track these upcoming events
Q3 FY27 financial results — check if revenue growth sustains above ₹18,000 million.
Future management commentary on foreign operations and exchange differences.
Updates on material costs and other expenses for sustained profit margins.
LOW RISK The filing reports strong financial results with no new risks identified, indicating stable performance.
💡 Investor Takeaway
Gland Pharma's consolidated net profit for Q2 FY27 increased 58.26% YoY to ₹2,907.56 million, up from ₹1,836.84 million. Revenue from operations also rose 23.32% YoY to ₹18,335.88 million. Half-year net profit was ₹6,077.15 million, reflecting sustained performance.
⚖️ Strengths & Concerns

✅ Positives

  • Consolidated Net Profit for Q2 FY27 increased to ₹2,907.56 million from ₹1,836.84 million in Q2 FY26, a 58.26% YoY rise.
  • Consolidated Revenue from Operations grew to ₹18,335.88 million in Q2 FY27 from ₹14,868.75 million in Q2 FY26, showing 23.32% YoY growth.

⚠️ Concerns

  • Total Other Comprehensive (Income)/Loss, net off tax, was a loss of ₹237.66 million in Q2 FY27, compared to a loss of ₹1,028.27 million in Q2 FY26.
  • Exchange differences on translation of foreign operations resulted in a loss of ₹270.28 million in Q2 FY27, compared to a loss of ₹1,014.23 million in Q2 FY26.
📅 Company Track Record
Gland Pharma previously reported Q4 FY26 revenue up 22% YoY to ₹17,428 Million with adjusted PAT up 97%. The company also recommended a final dividend of Rs. 20 per share for FY26. This Q2 FY27 filing continues to show strong revenue and PAT growth.

Based on publicly available historical data. For context only.

❓ Frequently Asked Questions
What was Gland Pharma's consolidated revenue from operations in Q2 FY27?
Gland Pharma's consolidated revenue from operations was ₹18,335.88 million for the quarter ended September 30, 2026, compared to ₹14,868.75 million in Q2 FY26.
What was Gland Pharma's consolidated net profit for the quarter ended September 30, 2026?
The consolidated net profit for Gland Pharma for Q2 FY27 was ₹2,907.56 million, an increase from ₹1,836.84 million in the corresponding quarter of the previous year.
How did Gland Pharma's half-year financial performance compare year-over-year?
For the half-year ended September 30, 2026, consolidated revenue from operations was ₹36,338.59 million (up from ₹29,924.97 million), and consolidated net profit was ₹6,077.15 million (up from ₹3,991.66 million).
What was Gland Pharma's total comprehensive income for Q2 FY27?
Gland Pharma's total comprehensive income for Q2 FY27 was ₹3,145.22 million, compared to ₹2,865.11 million in the same quarter of the prior year.

Questions based on this BSE filing only. For information purposes.

You've read one filing

There are 32,000 more, and one of them is about a company you own

Follow a company and we'll email you the moment it files again - explained, not just forwarded. Free.

  • Follow companies and get filings by email
  • Save any filing to read later
  • Two full AI analyses every month, free

No card needed. Sign in with Google in two taps.

⚠️ For Information Only - Not Investment Advice
ForgeUp Filings provides AI-generated summaries of public BSE exchange announcements (equity segment) for informational purposes only. Nothing here constitutes investment advice or a recommendation to buy, sell, or hold any security. ForgeUp is not a SEBI-registered investment advisor. All financial numbers are sourced directly from BSE filings and shown as-is. Past data is historical only. Please consult a qualified financial advisor before making investment decisions. Data sourced from BSE India public disclosures.
🔍
Sign in to use filters
Sign in free with Google to filter filings by category, market cap and sector - takes 5 seconds.